A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual‐responsive and CD206...
A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual‐responsive and CD206 targeting to improve the anti‐tumour effect
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
As a first‐line anticancer drug, paclitaxel has shortcomings, such as poor solubility and lack of tumour cell selectivity, which limit its further applications in clinical practice. Therefore, the authors aimed to utilise the characteristics of prodrug and nanotechnology to prepare a reactive oxygen species (ROS) and GSH dual‐responsive targeted tu...
Alternative Titles
Full title
A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual‐responsive and CD206 targeting to improve the anti‐tumour effect
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a83e4512c43a4b89aac0a25b90d4a444
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a83e4512c43a4b89aac0a25b90d4a444
Other Identifiers
ISSN
1751-8741
E-ISSN
1751-875X
DOI
10.1049/nbt2.12119
